Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 8/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238542 | 1.00 | NR1H2 (0.39) | NR1H2MMP2ANPEPCYP1A2POLB | |
| SCHEMBL13636363 | 1.00 | NR1H2 (0.39) | NR1H2MMP2ANPEPCYP1A2POLB | |
| SCHEMBL8064826 | 1.00 | NR1H2 (0.39) | NR1H2MMP2ANPEPCYP1A2POLB | |
| SCHEMBL28995745 | 0.87 | CYP1A2 (0.44) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1722643 | 0.87 | CYP1A2 (0.44) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL10238568 | 0.87 | CYP1A2 (0.44) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1462675 | 0.87 | CYP1A2 (0.44) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1439401 | 0.87 | CYP1A2 (0.44) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1949659 | 0.87 | CYP1A2 (0.44) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL16376318 | 0.86 | NR1H2 (0.42) | NR1H2CYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1262500-B1 | Catalyst for production of a polyurethane resin and method for producing a polyurethane resin | TOSOH CORP (JP) | 2015-12-30 | — | — | EP | claimed |
| EP-1262500-A1 | Catalyst for production of a polyurethane resin and method for producing a polyurethane resin | Tosoh Corporation (JP) | 2002-12-04 | — | — | EP | claimed |
| WO-2023032827-A1 | POLYURETHANE-CONTAINING NON-FOAMED MOLDED BODY | キヤノン株式会社 | 2023-03-09 | — | — | WO | disclosed |
| EP-1262500-B1 | Catalyst for production of a polyurethane resin and method for producing a polyurethane resin | TOSOH CORP (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-1409463-B1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL MYERS SQUIBB CO (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1242385-B1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-7479495-B2 | N-heterocyclic inhibitors of TNF-α expression | PHARMACOPEIA, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20050239770-A1 | N-heterocyclic inhibitors of TNF-alpha expression | MORIARTY KEVIN J | 2005-10-27 | — | — | US | disclosed |
| US-6906067-B2 | N-heterocyclic inhibitors of TNF-α expression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1262500-A1 | Catalyst for production of a polyurethane resin and method for producing a polyurethane resin | Tosoh Corporation (JP) | 2002-12-04 | — | — | EP | disclosed |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | PHARMACEOPEIA, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1242385-A1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | PHARMACOPEIA, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2001047897-A1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA, INC. (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239770-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, RELA, NFKBIA | NR1H2 1322/4885MMP2 1074/4885ANPEP 1212/4885 |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | NR1H2 1378/4885MMP2 1120/4885ANPEP 1460/4885 |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | NR1H2 1378/4885MMP2 1120/4885ANPEP 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.